The following episode covers my intro to the episode and thoughts on the topic of new innovations used in hospitals as part of procedure including bloodstream infections and dialysis.
Oh, hey, some unexpected news. This interview is unavailable at this time. One of these days we may be able to make it available, and if so, this will be announced in our weekly email. So please subscribe by going over to our website at RelentlessHealthValue.com.
The episode emphasizes the remarkable progress made by the Relentless Tribe in improving outcomes for chronic kidney disease (CKD) patients and highlights the obstacles hospitals face in adopting expensive new technologies under the DRG payment model. The discussion also covers the significant impact of hospital-acquired infections, particularly those leading to sepsis, and explores the role of Medicare's NTAP (new technology add-on payment) in incentivizing the use of innovative treatments. The episode underscores the complex balance between cost and patient outcomes in healthcare.
00:00 Introduction to Episode 411
00:36 Acknowledging the Relentless Tribe
02:30 Interview with Secretary David Shulkin and Erin Mistry
03:53 The Issue of Bloodstream Infections
04:52 Understanding DRG and Hospital Economics
06:19 Medicare's NTAP and Hospital Payments
07:44 Guest Backgrounds and Acknowledgements
08:43 Acronym Alerts and NTAP Recap
09:54 Conclusion and Subscription Information
Relentless Health Value